Preoperative p27 status is an independent predictor of prostate specific antigen failure following radical prostatectomy.

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Journal of Urology

• Publication date

  2003-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/01.JU.0000054004.08958.F3PMID 12629353
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Percent prostate needle biopsy tissue with cancer is more predictive of biochemical failure or adverse pathology after radical prostatectomy than prostate specific antigen or Gleason score.

  2002cited by this paper
• The role of imaging studies and molecular markers for selecting candidates for radical prostatectomy.

  2001cited by this paper
• Pten and p27KIP1 cooperate in prostate cancer tumor suppression in the mouse

  2001cited by this paper
• The cell cycle inhibitors p21WAF1 and p27KIP1 are associated with survival in patients treated by salvage prostatectomy after radiation therapy.

  2000cited by this paper
• Race is not an independent predictor of biochemical recurrence after radical prostatectomy in an equal access medical center.

  2000cited by this paper
• Prognostic value of cell cycle proteins p27(kip1) and MIB-1, and the cell adhesion protein CD44s in surgically treated patients with prostate cancer.

  2000cited by this paper
• Multiple functions of p27Kip1 and its alterations in tumor cells: a review

  2000cited by this paper
• Multivariate analysis of race and adverse pathologic findings after radical prostatectomy.

  2000cited by this paper
• Preoperative prostate needle biopsy p27 correlates with subsequent radical prostatectomy p27, Gleason grade and pathological stage.

  2000cited by this paper
• Predictive value of decreased p27Kip1 protein expression for the recurrence-free and long-term survival of prostate cancer patients

  1999cited by this paper
• Levels of expression of p27KIP1 protein in human prostate and prostate cancer: an immunohistochemical analysis.

  1999cited by this paper
• Loss of cyclin-dependent kinase inhibitor p27Kip1 is a novel prognostic factor in localized human prostate adenocarcinoma.

  1998cited by this paper
• Prognostic Markers in Localized Prostate Cancer: From Microscopes to Molecules

  1998cited by this paper
• Association of p27Kip1 levels with recurrence and survival in patients with stage C prostate carcinoma.

  1998cited by this paper
• A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer.

  1998cited by this paper
• Expression of p27kip1 in prostatic adenocarcinoma.

  1998cited by this paper
• Low p27 expression predicts poor disease-free survival in patients with prostate cancer.

  1998cited by this paper
• Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer.

  1998cited by this paper
• Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals.

  1994cited by this paper
• Evaluation of Radical Prostatectomy Specimens: A Comparative Analysis of Sampling Methods

  1992cited by this paper
• Classification of prostatic carcinomas.

  1966cited by this paper
• Classification of prostatic carcinomas.

  1966cited by this paper

• miR‐196a‐mediated downregulation of p27kip1 protein promotes prostate cancer proliferation and relates to biochemical recurrence after radical prostatectomy

  2020cites this paper
• Comprehensive analysis of biomarkers for prostate cancer based on weighted gene co-expression network analysis

  2020cites this paper
• Genetic signatures on prostate biopsy: clinical implications

  2018influential citation
• Molecular alterations associated with prostate cancer

  2018cites this paper
• Long non-coding RNA GAS5 and ZFAS1 are prognostic markers involved in translation targeted by miR-940 in prostate cancer

  2017cites this paper
• Antitumoral action of icaritin in LNCaP prostate cancer cells by regulating PEA3/HER2/AR signaling

  2016cites this paper
• Biomarkers for evaluation of prostate cancer prognosis.

  2015cites this paper
• Discovery and validation of prognostic tissue markers in clinical prostate cancer

  2015cites this paper
• Prognostic prediction following radical prostatectomy for prostate cancer using conventional as well as molecular biological approaches

  2013cites this paper
• Biomarkers of Potential Therapeutic Value

  2013cites this paper
• [Prostate cancer: promising biomarkers related to aggressive disease].

  2012cites this paper
• Beyond PSA: Promising New Markers for Prostate Cancer

  2012cites this paper
• CDK inhibitor VMY-1-103 causes cell cycle arrest and apoptosis in cancer cell lines

  2012cites this paper
• Molecular Genetics and Cancer Biology

  2012cites this paper
• The role of treatment modality on the utility of predictive tissue biomarkers in clinical prostate cancer: a systematic review

  2012cites this paper
• Cáncer de próstata: biomarcadores prometedores relacionados con la enfermedad agresiva

  2012cites this paper
• Low dosed interferon alpha augments the anti‐tumor potential of histone deacetylase inhibition on prostate cancer cell growth and invasion

  2012cites this paper
• The impact of Skp2 overexpression on recurrence-free survival following radical prostatectomy.

  2011cites this paper
• Inhibition of cyclin-dependent kinase phosphorylation of FOXO1 and prostate cancer cell growth by a peptide derived from FOXO1.

  2011cites this paper
• Cysteine‐rich secretory protein 3 and β‐microseminoprotein on prostate cancer needle biopsies do not have predictive value for subsequent prostatectomy outcome

  2011cites this paper
• Applications of Proteomics in Prostate Cancer

  2010cites this paper
• Is there a role for chemotherapy in nonmetastatic prostate cancer?

  2010cites this paper
• Expression of potential molecular markers in prostate cancer: correlation with clinicopathological outcomes in patients undergoing radical prostatectomy.

  2010cites this paper
• The Elevated Expression of a Mismatch Repair Protein Is a Predictor for Biochemical Recurrence After Radical Prostatectomy

  2009cites this paper
• Biomolecular markers of outcome prediction in prostate cancer

  2009cites this paper
• ANÁLISE DO VALOR PROGNÓSTICO DOS MARCADORES IMUNO- HISTOQUÍMICOS P27, MIB1 E CD34 NO CARCINOMA DE PRÓSTATA LOCALIZADO

  2009cites this paper
• TUMOR MARKERS IN PROSTATE CANCER DIAGNOSIS NÁDOROVÉ MARKERY KARCINOMU PROSTATY

  2008cites this paper
• Molecular and prognostic markers in prostate cancer

  2008cites this paper
• Molecular profiling of prostate cancer

  2008cites this paper
• CDKN1B V109G Polymorphism Frequency and Prostate Cancer Risk in Taiwan

  2008cites this paper
• The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy

  2008cites this paper
• Expression of p27(Kip1), cyclin D3 and Ki67 in BPH, prostate cancer and hormone-treated prostate cancer cells

  2008cites this paper
• Nádorové markery karcinomu prostaty

  2008cites this paper
• Tumor markers in prostate cancer diagnosis

  2008cites this paper
• Pathologic Implications of Prostate Biopsy

  2008cites this paper
• Prognostic significance of p27Kip1 expression in bladder cancer

  2007cites this paper
• A novel anticancer agent, icaritin, induced cell growth inhibition, G1 arrest and mitochondrial transmembrane potential drop in human prostate carcinoma PC-3 cells.

  2007cites this paper
• Molecular markers in the diagnosis of prostate cancer.

  2007cites this paper
• Molecular staging of prostate cancer in the year 2007

  2007cites this paper
• Molecular markers in the diagnosis of prostate cancer

  2007cites this paper
• Single nucleotide polymorphisms: early diagnosis and risk assessment in genitourinary malignancy.

  2006cites this paper
• Biological correlates of p27 compartmental expression in prostate cancer.

  2006cites this paper
• Percentage of positive biopsies associated with freedom from biochemical recurrence after low-dose-rate prostate brachytherapy alone for clinically localized prostate cancer.

  2006cites this paper
• Recent advances in the field of urology

  2006cites this paper
• A novel anticancer agent, decursin, induces G1 arrest and apoptosis in human prostate carcinoma cells.

  2005cites this paper
• Apoptosis in Human Prostate Carcinoma Cells Arrest and 1 A Novel Anticancer Agent , Decursin , Induces G Updated

  2005cites this paper
• A novel anticancer agent, decursin, induces G1 arrest and apoptosis in human prostate carcinoma cells

  2005cites this paper
• A Simple Inexpensive Method for the Production of Tissue Microarrays from Needle Biopsy Specimens: Examples with Prostate Cancer

  2005cites this paper
• Genetic alterations in prostate cancer

  2004cites this paper
• What's new in urology.

  2004cites this paper
• Update of staging and risk assessment for prostate cancer patients

  2004cites this paper
• Reduction of PTEN and p27kip1 expression correlates with tumor grade in prostate cancer. Analysis in radical prostatectomy specimens and needle biopsies

  2004cites this paper
• Management of PSA Recurrence After Definitive Therapy for Prostate Cancer

  2004cites this paper
• in prostate cancer. Analysis in radical prostatectomy specimens and needle biopsies

  2004cites this paper
• Genetic alterations in prostate cancer

  2004cites this paper
• Molecular markers and prostate cancer prognosis.

  2004cites this paper
• Predicting biochemical recurrence after radical prostatectomy for patients with organ-confined disease using p27 expression.

  2003cites this paper
• Molecular markers to identify patients at risk for recurrence after primary treatment for prostate cancer.

  2003cites this paper
• The reporting of prostate cancer on needle biopsy: prognostic and therapeutic implications and the utility of diagnostic markers.

  2003cites this paper